Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2

Conditions

Lymphoma 200Leukemia 159Leukemia, Myeloid, Acute 134Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Lymphoma, Non-Hodgkin 111Multiple Myeloma 110Lymphoma, Large B-Cell, Diffuse 108Lymphoma, Follicular 93Hodgkin Disease 91Burkitt Lymphoma 91Myelodysplastic Syndromes 87Lymphoma, Mantle-Cell 87Leukemia, Lymphocytic, Chronic, B-Cell 84Breast Neoplasms 84Lymphoma, Large-Cell, Immunoblastic 73Lymphoma, B-Cell, Marginal Zone 59Sarcoma 54Neoplasms, Plasma Cell 50Neuroblastoma 49Central Nervous System Neoplasms 46Leukemia, Myeloid, Chronic-Phase 43Recurrence 40Ovarian Neoplasms 39Leukemia, Myeloid, Accelerated Phase 39Congenital Abnormalities 39Myeloproliferative Disorders 38Dendritic Cell Sarcoma, Interdigitating 38Blast Crisis 34Leukemia, Myelomonocytic, Chronic 32Neutropenia 29

Interventions

Dexamethasone 12Bortezomib 9Lenalidomide 7Cyclophosphamide 5isatuximab 3fludarabine 3daratumumab 3Granulocyte Colony-Stimulating Factor 3pomalidomide 2filanesib 2dacetuzumab 2Tacrolimus 2Steroids 2Injections, Subcutaneous 2Filgrastim 2Clinical Protocols 2Calcium Dobesilate 2Alemtuzumab 2plerixafor 1ofatumumab 1nirogacestat 1fludarabine phosphate 1ficlatuzumab 1epratuzumab 1birtamimab 1Zoledronic Acid 1Whole-Body Irradiation 1Vorinostat 1Thalidomide 1Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Paraproteinemias × Filgrastim × Clear all
NCT00821249 2020-10-19

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Pfizer

Phase 1/2 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

NCT01248923 2020-09-30

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Array BioPharma

Phase 1 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡